SCM
IOBT

Soleus Capital Management’s IO Biotech IOBT Stock Holding History

Soleus Capital Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-192,670
Closed -$268K – 99
2025
Q2 		$268K Hold
192,670
– – 0.02% 93
2025
Q1 		$210K Hold
192,670
– – 0.02% 74
2024
Q4 		$177K Hold
192,670
– – 0.01% 81
2024
Q3 		$202K Hold
192,670
– – 0.02% 87
2024
Q2 		$225K Buy
+192,670
New +$269K 0.02% 91
2022
Q4 		– Sell
-288,119
Closed -$781K – 81
2022
Q3 		$781K Sell
288,119
-367,285
-56% -$1.36M 0.11% 71
2022
Q2 		$3.06M Sell
655,404
-17,330
-3% -$106K 0.48% 55
2022
Q1 		$3.56M Hold
672,734
– – 0.46% 46
2021
Q4 		$4.3M Buy
+672,734
New +$6.5M 0.43% 41

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Soleus Capital Management's IOBT Position: Q3 2025 in Review

Soleus Capital Management sold out of IO Biotech (IOBT) in Q3 2025, closing a stake of 192,670 shares — an estimated $268K sold.

Soleus Capital Management first reported a position in IOBT in Q4 2021 and held it in 9 quarters. The position peaked at $4.3M in Q4 2021. 21 funds tracked by Wall St. Rank hold IOBT as of Q3 2025.

  • Soleus Capital Management reported no remaining IO Biotech position as of Q3 2025 after selling out during the quarter.
  • Soleus Capital Management sold 192,670 IO Biotech shares in Q3 2025, an estimated $268K.
  • Soleus Capital Management first reported a position in IO Biotech in Q4 2021 and held it in 9 quarters.
  • Soleus Capital Management's IO Biotech position peaked at $4.3M in Q4 2021.
  • 21 funds tracked by Wall St. Rank held IO Biotech as of Q3 2025.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.